Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

01-08-2013 | Original Paper

Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study

Auteurs: Justine M. Kent, Stuart Kushner, Xiaoping Ning, Keith Karcher, Seth Ness, Michael Aman, Jaskaran Singh, David Hough

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 8/2013

Abstract

Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to <45 kg], 0.175 mg/day [>45 kg] or high-dose: 1.25 mg/day [20 to <45 kg], 1.75 mg/day [>45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(−12.4 [6.5]; p < 0.001), but not low-dose (−7.4 [8.1]; p = 0.164) group, versus placebo (−3.5 [10.7]). Clinical Global Impressions-Severity and Children’s Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently.

vorige artikel Psychological Correlates of Handedness and Corpus Callosum Asymmetry in Autism: The left Hemisphere Dysfunction Theory Revisited

volgende artikel Empirically Based Phenotypic Profiles of Children with Pervasive Developmental Disorders: Interpretation in the Light of the DSM-5

Aman, M. G., Arnold, L. E., McDougle, C. J., Vitiello, B., Scahill, L., Davies, M., et al. (2005). Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology, 15(6), 869–884.PubMedCrossRef

Aman, M. G., & Singh, N. N. (1994). Aberrant behavior checklist—community. (supplementary manual). East Aurora, NY: Slosson Educational Publication.

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985a). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89(5), 485–491.PubMed

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985b). Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency, 89(5), 492–502.PubMed

Aman, M. G., Vinks, A. A., Remmerie, B., Mannaert, E., Ramadan, Y., Masty, J., et al. (2007). Plasma pharmacokinetics characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorder. Clinical Therapeutics, 29, 1476–1486.PubMedCrossRef

Anderson, G. M., Scahill, L., McCracken, J. T., McDougle, C. J., Aman, M. G., Tierney, E., et al. (2007). Effect of short- and long-term risperidone treatment on prolactin levels in children with autism. Biological Psychiatry, 61(4), 545–550.PubMedCrossRef

Arnold, L. E., Vitiello, B., Mcdougle, C., Scahill, L., Shah, B., Gonzalez, N. M., et al. (2003). Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry, 42(12), 1443–1450.PubMedCrossRef

Barnes, T. R. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.PubMedCrossRef

Findling, R. L., Kusumakar, V., Daneman, D., Moshang, T., De Smedt, G., & Binder, C. (2003). Prolactin levels during long-term risperidone treatment in children and adolescents. Journal of Clinical Psychiatry, 64(11), 1362–1369.PubMedCrossRef

Freitag, C. M. (2007). The genetics of autistic disorders and its clinical relevance: A review of the literature. Molecular Psychiatry, 12(1), 2–22.PubMedCrossRef

Gagliano, A., Germano, E., Pustorino, G., Impallomeni, C., D’arrigo, C., Calamoneri, F., et al. (2004). Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. Journal of Child and Adolescent Psychopharmacology, 14(1), 39–47.PubMedCrossRef

Guy, W. (Ed.). (1976a). Clinical Global Impression (CGI). ECDEU assessment manual for psychopharmacology. National Institute of Mental Health (pp. 218–222). Rockville, Maryland: Welfare publication.

Guy, W. (Ed.). (1976b). AIMS. Abnormal Involuntary Movement Scale. ECDEU Assessment for Psychopharmacology. Rev. Ed, National Institute of Mental Health (pp. 537–543). Rockville, Maryland: Welfare publication.

Libbey, J. E., Sweeten, T. L., McMahon, W. M., & Fujinami, R. S. (2005). Review: Autistic disorder and viral infections. Journal of Neurovirology, 11, 1–10.PubMedCrossRef

Lieberman, J. A. (2004). Metabolic changes associated with antipsychotic use. Prim Care Campanion. Journal of Clinical Psychiatry, 6(2), 8–13.

Limperopoulos, C., Bassan, H., Gauvreau, K., Robertson, R. L., Jr, Sullivan, N. R., Benson, C. B., et al. (2007). Does cerebellar injury in premature infants contribute to the high prevalence of long-term cognitive, learning, and behavioral disability in survivors? Pediatrics, 120(3), 584–593.PubMedCrossRef

Malone, R. P., Maislin, G., Choudhury, M. S., Gifford, C., & Delaney, M. A. (2002). Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. Journal of the American Academy of Child and Adolescent Psychiatry, 41(2), 140–147.PubMedCrossRef

Mc Dougle, C. J., Stigler, K. A., & Posey, D. J. (2003). Treatment of aggression in children and adolescent with autism and conduct disorder. Journal of Clinical Psychiatry, 64(4), 16–25.

McCracken, J. T., Mcgough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321.PubMedCrossRef

Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 37(4), 372–376.PubMedCrossRef

Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 37(2), 367–373.PubMedCrossRef

Persico, A. M., & Bourgeron, T. (2006). Searching for ways out of the autism maze: Genetic, epigenetic and environmental clues. Trends in Neurosciences, 29(7), 349–358.PubMedCrossRef

Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., & Eerdekens, M. (2006). A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. American Journal of Psychiatry, 163, 402–410.PubMedCrossRef

Risperdal^® Prescribing Information (revised 2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020272s065,020588s053,021444s041lbl.pdf.

RUPP. (2005). Research units on pediatric psychopharmacology autism network. Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry, 162, 1361–1369.CrossRef

Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., et al. (1997). Children’s yale-brown obsessive compulsive scale: Reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36(6), 844–852.PubMedCrossRef

Schultz, R. T. (2005). Developmental deficits in social perception in autism: The role of the amygdala and fusiform face area. International Society for Developmental Neuroscience, 23, 125–141.CrossRef

Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634–e641.PubMedCrossRef

Simpson, G. M., & Angus, J. W. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. Supplementum, 212, 11–19.PubMedCrossRef

Szpir, M. (2006). Tracing the origins of autism: A spectrum of new studies. Environmental Health Perspectives, 114(7), A412–A418.PubMedCrossRef

Thyssen, A., Vermeulen, A., Fuseau, E., Fabre, M., & Mannaert, E. (2010). Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clinical Pharmacokinetics, 49(7), 465–478.PubMedCrossRef

Troost, P. W., Lahuis, B. E., Steenhuis, M. P., Ketelaars, C. E. J., Buitelaar, J. K., & Van England, H. (2005). Long-trem effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry, 44(11), 1137–1144.PubMedCrossRef

Tschoner, A., Engl, J., Lamier, M., Kaser, S., Rettenbacher, M., Fleischhacker, J. R., et al. (2007). Review: Metabolic side effect of antipsychotic medication. International Journal of Clinical Practice, 61(8), 1356–1370.PubMedCrossRef

Turgay, A., Binder, C., Snyder, R., & Fisman, S. (2002). Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics, 110(3), 1–12.CrossRef

Titel: Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study
Auteurs: Justine M. Kent
Stuart Kushner
Xiaoping Ning
Keith Karcher
Seth Ness
Michael Aman
Jaskaran Singh
David Hough
Publicatiedatum: 01-08-2013
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 8/2013
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-012-1723-5

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 8/2013

J. Thierfeld Brown, L. Wolf, L. King, and R. Kukiela Bork: The Parent’s Guide to College for Students on the Autism Spectrum

The Association Between Child Autism Symptomatology, Maternal Quality of Life, and Risk for Depression

Enhanced Access to Early Visual Processing of Perceptual Simultaneity in Autism Spectrum Disorders

Viewing Social Scenes: A Visual Scan-Path Study Comparing Fragile X Syndrome and Williams Syndrome

Real World Executive Control Impairments in Preschoolers with Autism Spectrum Disorders

Atypical Pupillary Light Reflex and Heart Rate Variability in Children with Autism Spectrum Disorder